Semaglutide Protects Testicular Function From Diabetic Damage in Rats
Semaglutide improved testicular function, sperm parameters, and reproductive hormone levels in diabetic rats, suggesting GLP-1 drugs may protect male fertility from diabetes-related damage.
Quick Facts
What This Study Found
Semaglutide improved sperm parameters, reproductive hormones, and testicular histology in diabetic rats by reducing oxidative stress and inflammation.
Key Numbers
28 adult male rats were divided into 4 groups (7 per group). Specific testicular function measurements were analyzed but not detailed in the available abstract.
How They Did This
Diabetic rat model treated with semaglutide. Assessed sperm count, motility, morphology, reproductive hormones, testicular histology, oxidative stress, and inflammatory markers.
Why This Research Matters
Diabetes-related male infertility affects millions. If GLP-1 drugs protect testicular function alongside metabolic benefits, diabetic men on these drugs may preserve fertility better.
The Bigger Picture
GLP-1 drugs continue to reveal protective effects across virtually every organ system — now including male reproductive organs. For diabetic men concerned about fertility, GLP-1 drugs may offer dual metabolic and reproductive benefits.
What This Study Doesn't Tell Us
Rat study. Human male reproductive responses to GLP-1 drugs may differ. Effects of weight loss vs direct GLP-1R activation on testes are not separated.
Questions This Raises
- ?Do diabetic men on semaglutide show better fertility outcomes than those on other diabetes drugs?
- ?Is the testicular protection from direct GLP-1R activation or secondary to improved metabolic health?
- ?Could GLP-1 drugs be recommended specifically for diabetic men with fertility concerns?
Trust & Context
- Key Stat:
- Fertility protected Semaglutide improved sperm parameters and reproductive hormones in diabetic rats, adding male fertility protection to GLP-1 benefits
- Evidence Grade:
- Preliminary evidence: rat diabetes model with reproductive outcome assessment. No human fertility data.
- Study Age:
- Published in 2024. Expands GLP-1 protective effects to male reproductive health.
- Original Title:
- Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.
- Published In:
- Steroids, 213, 109537 (2025)
- Authors:
- Abdel-Wahab, Basel A, El-Shoura, Ehab A M, Habeeb, Mohammed S, Aldabaan, Nayef A, Ahmed, Yasmine H, Zaafar, Dalia
- Database ID:
- RPEP-09734
Evidence Hierarchy
Frequently Asked Questions
Can diabetes affect male fertility?
Yes — diabetes damages blood vessels and nerves throughout the body, including the testes. It can reduce sperm quality, lower testosterone, and impair erectile function. This study shows semaglutide can reverse some of this damage in diabetic rats.
Does semaglutide help with male fertility?
In diabetic rats, semaglutide improved sperm count, quality, and reproductive hormones. While human studies are needed, diabetic men taking GLP-1 drugs may be getting some fertility protection as a side benefit of their metabolic treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09734APA
Abdel-Wahab, Basel A; El-Shoura, Ehab A M; Habeeb, Mohammed S; Aldabaan, Nayef A; Ahmed, Yasmine H; Zaafar, Dalia. (2025). Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.. Steroids, 213, 109537. https://doi.org/10.1016/j.steroids.2024.109537
MLA
Abdel-Wahab, Basel A, et al. "Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.." Steroids, 2025. https://doi.org/10.1016/j.steroids.2024.109537
RethinkPeptides
RethinkPeptides Research Database. "Unraveling the impact of semaglutide in a diabetic rat model..." RPEP-09734. Retrieved from https://rethinkpeptides.com/research/abdel-wahab-2025-unraveling-the-impact-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.